18F-FDG/PET May Help to Identify a Subgroup of Patients with T1-T2 Breast Cancer and 1-3 Positive Lymph Nodes Who Are at a High Risk of Recurrence after Mastectomy
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study is to assess the utility of positron emission tomography (PET) for predicting recurrence among patients with T1-T2/N1 breast cancer who were treated with mastectomy. Materials and Methods Of 712 consecutive patients with T1-T2/N1 breast cancer treated during 2003-2012, 109 had undergone preoperative 18F-fluorodeoxyglucose/PET and were included. Metabolic (maximum standardized uptake value [SUVmax]), volumetric (metabolic tumor volume [MTV]), and combined (total lesion glycolysis [TLG]) indices were measured. The resulting values were analyzed and compared with clinical outcome. Results At the median follow-up of 46.7 months, the 3-year relapse-free survival (RFS) rate was 95.2%. SUVmax (area under curve, 0.824) was more useful than MTV or TLG as a means of identifying patients at high risk for any recurrence. In multivariate analysis, SUVmax remained an independent risk factor for RFS (p=0.006). Using the method of Contal and O’Quigley, a SUVmax threshold of 5.36 showed the best predictive performance. The PET-based highrisk group (! 5.36 in either breast or nodes) had more T1c-T2, high-grade, hormone-receptor negative, and invasive ductal carcinoma tumors than the low-risk group (< 5.36 in both breast and nodes). The prognosis was much worse when high SUVmax (! 5.36) was detected in nodes (p < 0.001). In the no-radiotherapy cohort, the PET-based high-risk group had increased risk of locoregional recurrence when compared to the low-risk group (p=0.037). Conclusion High SUVmax on preoperative PET showed association with elevated risk of locoregional recurrence and any recurrence. Pre-treatment PET may improve assessments of recurrence risk and clarify indications for post-mastectomy radiotherapy in this subset of patients.
Abstract
Purpose The purpose of this study is to assess the utility of positron emission tomography (PET) for predicting recurrence among patients with T1-T2/N1 breast cancer who were treated with mastectomy. Materials and Methods Of 712 consecutive patients with T1-T2/N1 breast cancer treated during 2003-2012, 109 had undergone preoperative 18F-fluorodeoxyglucose/PET and were included. Metabolic (maximum standardized uptake value [SUVmax]), volumetric (metabolic tumor volume [MTV]), and combined (total lesion glycolysis [TLG]) indices were measured. The resulting values were analyzed and compared with clinical outcome. Results At the median follow-up of 46.7 months, the 3-year relapse-free survival (RFS) rate was 95.2%. SUVmax (area under curve, 0.824) was more useful than MTV or TLG as a means of identifying patients at high risk for any recurrence. In multivariate analysis, SUVmax remained an independent risk factor for RFS (p=0.006). Using the method of Contal and O’Quigley, a SUVmax threshold of 5.36 showed the best predictive performance. The PET-based highrisk group (! 5.36 in either breast or nodes) had more T1c-T2, high-grade, hormone-receptor negative, and invasive ductal carcinoma tumors than the low-risk group (< 5.36 in both breast and nodes). The prognosis was much worse when high SUVmax (! 5.36) was detected in nodes (p < 0.001). In the no-radiotherapy cohort, the PET-based high-risk group had increased risk of locoregional recurrence when compared to the low-risk group (p=0.037). Conclusion High SUVmax on preoperative PET showed association with elevated risk of locoregional recurrence and any recurrence. Pre-treatment PET may improve assessments of recurrence risk and clarify indications for post-mastectomy radiotherapy in this subset of patients.
참고문헌 (19)
- Clarke M, "Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival : an overview of the randomised trials", Lancet, 366, pp.2087~2106 (2005)
- EBCTCG(Early Breast Cancer Trialists' Collaborative Group), "Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality : metaanalysis of individual patient data for 8135 women in 22 randomised trials", Lancet, 383, pp.2127~2135 (2014)
- Poortmans P, "Postmastectomy radiation in breast cancer with one to three involved lymph nodes : ending the debate", Lancet, 383, pp.2104~2106 (2014)
- Wallgren A, "Risk factors for locoregional recurrence among breast cancer patients : results from International Breast Cancer Study Group Trials I through VII", J Clin Oncol, 21, pp.1205~1213 (2003)
- Taghian A, "Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy : results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials", J Clin Oncol, 22, pp.4247~4254 (2004)
- Langer A, "A systematic review of PET and PET", CT in oncology : a way to personalize cancer treatment in a cost-effective manner?, 2010, pp.10, 283~
- Yun M, "Lymph node staging of gastric cancer using(18)F-FDG PET : a comparison study with CT", J Nucl Med, 46, pp.1582~1588 (2005)
- Liao S, "Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer", Eur J Nucl Med Mol Imaging, 39, pp.27~38 (2012)
- Contal C, "An application of changepoint methods in studying the effect of age on survival in breast cancer", Comput Stat Data Anal, 30, pp.253~270 (1999)
- Osborne JR, "18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value : microarray and immunohistochemical analysis", J Nucl Med, 51, pp.543~550 (2010)
- Mavi A, "The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions", J Nucl Med, 48, pp.1266~1272 (2007)
- Baba S, "Diagnostic and prognostic value of pretreatment SUV in 18F-FDG", PET in breast cancer : comparison with apparent diffusion coefficient from diffusion-weighted MR imaging, 2014, pp.55, 736~742
- Song BI, "18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET", CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer, 2012, pp.53, 1337~1344
- Nakajima N, "Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography", computed tomography improve disease recurrence prediction in postmas-tectomy breast cancer patients with 1 to 3 positive axillary lymph nodes, 2013, pp.87, 738~746
- Groheux D, "The yield of 18F-FDG PET", CT in patients with clinical stage IIA, IIB, or IIIA breast cancer : a prospective study, 2011, pp.52, 1526~1534
- fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer : an Ontario clinical oncology group study, "J Clin Oncol", 2012, 1274~1279
- Groves AM, "Defining the role of PET-CT in staging early breast cancer", Oncologist, 17, pp.613~619 (2012)
- Riedl CC, "Retrospective analysis of 18F-FDG PET", CT for staging asymptomatic breast cancer patients younger than 40 years, 2014, pp.55, 1578~1583
- Groheux D, "Effect of(18)F-FDG PET", CT imaging in patients with clinical Stage II and III breast cancer, 2008, pp.71, 695~704